Drug
KW 0761
KW 0761: highest development phase Phase 3, developed by Kyowa Kirin. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| KW-0761 NCT01728805 | Phase 3 | Cutaneous T-Cell Lymphoma |
| KW-0761 (mogamulizumab) NCT01611142 | Phase 2 | Peripheral T-Cell Lymphoma |
| KW-0761 NCT01626664 | Phase 2 | Adult T-cell Leukemia-Lymphoma |
| KW-0761 NCT00888927 | Phase 1/2 | Peripheral T-Cell Lymphoma |
Latest
No recent events.
Follow KW 0761 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.